Wednesday, September 26, 2018

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Joint Venture Agreement with Asterion Cannabis Inc.


Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its entry into an agreement to form a joint venture focused on the development of a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches and other jointly evaluated products aimed at treating various ailments such as chronic pain, inflammation, epilepsy and anxiety disorders. “This agreement between PreveCeutical and Asterion further supports our mission to improve global health and healthcare by utilizing innovative science and cutting-edge technology to enhance natural products,” Stephen Van Deventer, chairman, CEO and president of PreveCeutical, stated in the news release. “Our joint venture with Asterion comes at an important time, using Asterion’s high quality, low cost, genetically uniform strains of medicinal cannabis will allow PreveCeutical to supply the anticipated increasing demand for effective and personalised cannabis-based therapies.”

To view the full press release, visit http://ibn.fm/Z2XVz

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information, visit the company’s website at www.PreveCeutical.com

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php


No comments: